HUTCHMED (China) Limited

HCMNASDAQHealthcare● Active

$10.85

$-0.02(-0.18%)

Market Cap$1.9B

P/E Ratio—

52W High$19.5

52W Low$10.73

Avg Volume39K

Open$10.90

Beta0.37

Overview

Stock ranking:Drug Manufacturers - Specialty & Generic·Healthcare·View All Market Cap Rankings →

HUTCHMED (China) Limited (HCM) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · HCM · as of Jun 8, 2026

Key Statistics

EPS (TTM)$2.77Earnings history

PE Ratio (TTM)3.9×PE Ratio deep dive

Revenue (TTM)$602.2MFull revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding171.7MShares outstanding history

Next EarningsAug 3, 2026Est.Earnings history

Explore HUTCHMED (China) Limited Data

Market Cap$1.9B

Analyst Forecast$14 · Buy

DividendsNo Dividend

Revenue$550.0M-12.73%

EarningsEPS $2.65+1104.55%

PE Ratio3.9×

Financial Snapshot

Full Financials

FY 2025Revenue$550.0M▼ 12.73% YoY

202320242025

FY 2025Net Income$458.1M▲ +1114.23% YoY

202320242025

FY 2025EPS$2.65▲ +1104.55% YoY

202320242025

TTM:Revenue: $602.2MNet Income: $466.9MEPS: $2.77View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy10 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$13.60Low

$10.85Current

$13.60Avg Target25.35% upside

$13.60High

Total: 10 · Buy rate: 80.0%

The HCM analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $13.60, representing +25.35% upside from the current price of $10.85.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

HCM

HUTCHMED (China) Limited

$10.85-0.18%$1.9B #2

ADPT

Adaptive Biotechnologies Corporation

$16.70-1.18%$2.7B #3

BHC

Bausch Health Companies Inc.

$5.11-4.84%$1.9B #4

CDTX

Cidara Therapeutics, Inc.

$221.38+0.00%$5.6B #5

CPRX

Catalyst Pharmaceuticals, Inc.

$31.28+0.03%$3.8B #6

IDYA

IDEAYA Biosciences, Inc.

$31.48+11.28%$2.8B

Stock Performance

Full History

1D-0.23%

1W-5.86%

1M-17.40%

3M-21.70%

YTD-18.64%

1Y-32.05%

5Y-64.44%

About HUTCHMED (China) Limited

CEOChig Fung Cheng

IPO DateMar 16, 2016

Employees1,811

CountryHK

Websitehutch-med.com

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related di…

Drug Manufacturers - Specialty & Generic HealthcareNASDAQADRHK

About Stock Overview & Key Data

HUTCHMED (China) Limited (HCM) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Mar 16, 2016. As of the latest trading session, HCM stock price is $10.85, with a market capitalization of $1.9B. The stock has returned -32.05% over the past 12 months and -18.64% year-to-date.

According to 10 Wall Street analysts, the consensus rating for HUTCHMED (China) Limited stock is Buy, with an average 12-month price target of $13.60. In fiscal year 2025, HUTCHMED (China) Limited reported revenue of $550.0M and net income of $458.1M. For detailed data — including HUTCHMED (China) Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, HUTCHMED (China) Limited (HCM) stock price is $10.85. The stock is traded on NASDAQ under the ticker symbol HCM. The 52-week range is $10.73 – $19.50.

HCM stock priceHCM quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice